Table 1.
Representative recombinant VLP-based human vaccines on the market
| Trade name | Manufacture (year of licensure) | Expression host | Structure | Potency marker | Reference |
|---|---|---|---|---|---|
| Recombivax HB (HBV) | Merck (1986) | Saccharomyces cerevisiae | Octahedral | RF-1, A1.2, 5F11 | 104,105,111,114,115,152 |
| Engerix-B (HBV) | GlaxoSmithKline (1988) | Saccharomyces cerevisiae | N/A | RF-1 | 153 |
| Gardasil (HPV) | Merck (2006) | Saccharomyces cerevisiae | Icosahedral | H16.V5, H18.R5, H11.B2, H6.B10.5 | 20,68,154,155 |
| Cervarix (HPV) | GlaxoSmithKline (2009) | Trichoplusiani/baculovirus | Icosahedral | H16.V5 | 156 |
| Hecolin (HEV) | Xiamen Innovax Biotech (2011) | Escherichia coli | N/A | 8C11, 8H3 | 8,21,31 |